-
Je něco špatně v tomto záznamu ?
A comparison of the acute effects of calcium and strontium ranelate on the serum marker of bone resorption
KB. Maresova, T. Franek, T. Vondracek, JJ. Stepan,
Jazyk angličtina Země Německo
Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
22080821
DOI
10.1515/cclm.2011.781
Knihovny.cz E-zdroje
- MeSH
- aplikace orální MeSH
- biologické markery krev MeSH
- dospělí MeSH
- kolagen typu I krev MeSH
- lidé MeSH
- mladý dospělý MeSH
- omezení příjmu potravy MeSH
- organokovové sloučeniny krev farmakologie MeSH
- parathormon krev MeSH
- peptidy krev MeSH
- referenční standardy MeSH
- regulace genové exprese účinky léků MeSH
- resorpce kosti krev MeSH
- thiofeny krev farmakologie MeSH
- vápník krev farmakologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
BACKGROUND: To investigate the mechanism by which strontium ranelate (SrR) inhibits the bone resorption, this study compared the effects of SrR and calcium on parathyroid hormone (PTH) and the biochemical marker of bone resorption (serum type 1 collagen cross-linked C-telopeptide, βCTX). METHODS: In 10 healthy young subjects, after overnight fasting, 1000 mg of elemental calcium and 2000 mg of SrR containing 600 mg Sr²⁺ were administered consecutively with a 1 week washout period. During the control period no drug was given. Fasting blood samples were drawn at baseline and throughout the next 5-h period. RESULTS: After the ingestion of either calcium or SrR, there was a significant increase in serum calcium and strontium concentrations, and a decrease in serum βCTX and intact PTH concentrations as compared to the baseline values (p<0.05). In the fasting subjects, no significant differences in the variable were found as compared to the baseline values. CONCLUSIONS: The decrease in PTH and the marker of bone resorption observed after the SrR administration is comparable to the decrease observed after the calcium administration in young adults.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000998
- 003
- CZ-PrNML
- 005
- 20130109111646.0
- 007
- ta
- 008
- 130108s2012 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1515/cclm.2011.781 $2 doi
- 035 __
- $a (PubMed)22080821
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Maresova, Kristyna Brabnikova $u Institute of Rheumatology, Faculty of Medicine 1, Charles University, Prague, Czech Republic. maresova.kristyna@seznam.cz
- 245 12
- $a A comparison of the acute effects of calcium and strontium ranelate on the serum marker of bone resorption / $c KB. Maresova, T. Franek, T. Vondracek, JJ. Stepan,
- 520 9_
- $a BACKGROUND: To investigate the mechanism by which strontium ranelate (SrR) inhibits the bone resorption, this study compared the effects of SrR and calcium on parathyroid hormone (PTH) and the biochemical marker of bone resorption (serum type 1 collagen cross-linked C-telopeptide, βCTX). METHODS: In 10 healthy young subjects, after overnight fasting, 1000 mg of elemental calcium and 2000 mg of SrR containing 600 mg Sr²⁺ were administered consecutively with a 1 week washout period. During the control period no drug was given. Fasting blood samples were drawn at baseline and throughout the next 5-h period. RESULTS: After the ingestion of either calcium or SrR, there was a significant increase in serum calcium and strontium concentrations, and a decrease in serum βCTX and intact PTH concentrations as compared to the baseline values (p<0.05). In the fasting subjects, no significant differences in the variable were found as compared to the baseline values. CONCLUSIONS: The decrease in PTH and the marker of bone resorption observed after the SrR administration is comparable to the decrease observed after the calcium administration in young adults.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a resorpce kosti $x krev $7 D001862
- 650 _2
- $a vápník $x krev $x farmakologie $7 D002118
- 650 _2
- $a kolagen typu I $x krev $7 D024042
- 650 _2
- $a omezení příjmu potravy $7 D005215
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese $x účinky léků $7 D005786
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a organokovové sloučeniny $x krev $x farmakologie $7 D009942
- 650 _2
- $a parathormon $x krev $7 D010281
- 650 _2
- $a peptidy $x krev $7 D010455
- 650 _2
- $a referenční standardy $7 D012015
- 650 _2
- $a thiofeny $x krev $x farmakologie $7 D013876
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Franek, Tomas
- 700 1_
- $a Vondracek, Tomas
- 700 1_
- $a Stepan, Jan J
- 773 0_
- $w MED00010886 $t Clinical chemistry and laboratory medicine : CCLM / FESCC $x 1434-6621 $g Roč. 50, č. 2 (2012), s. 333-5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22080821 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20130109111751 $b ABA008
- 999 __
- $a ok $b bmc $g 963780 $s 799162
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 50 $c 2 $d 333-5 $i 1434-6621 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
- LZP __
- $a Pubmed-20130108